Alle Storys
Folgen
Keine Story von Helsinn Healthcare SA mehr verpassen.

Helsinn Healthcare SA

Helsinn and Angelini announce a license agreement for ALOXI® in Portugal

Lugano, Switzerland and Lisboa, Portugal (ots)

HELSINN
HEALTHCARE SA, a Swiss pharmaceutical group, and ANGELINI
FARMACÊUTICA, a Portuguese Pharmaceutical company, announce the
signing of an agreement granting ANGELINI the exclusive License and
Distribution rights for ALOXI® (Palonosetron hydrochloride) in
PORTUGAL.
ALOXI® is a strong and long acting antiemetic belonging to the
second generation of serotonin (5-HT3) antagonists, the leading class
for the prevention of nausea and vomiting induced by chemotherapy.
ALOXI® has been granted a centralized registration in Europe last
March with the following indications:
- the prevention of acute nausea and vomiting associated with
     highly emetogenic cancer chemotherapy, and
   - the prevention of nausea and vomiting associated with moderately
      emetogenic cancer chemotherapy.
Nausea and Vomiting is still an important medical need for
chemotherapy treated patients. Updated International guidelines such
as the US National Comprehensive Cancer Network (NCCN) indicated
ALOXI® as the treatment of choice for the prevention of acute and
delayed nausea and vomiting due to moderately emetogenic
chemotherapies.
"We are delighted to sign this new agreement with ANGELINI and
extend our cooperation in Portugal to ALOXI®. We have enjoyed since a
few years now a successful relationship with ANGELINI in this
country", said Dr. Riccardo Braglia, Managing Director of HELSINN
HEALTHCARE SA.  "We look forward to strengthen our cooperation and to
a successful introduction of ALOXI® to the medical community and to
the patients".
"We are very pleased that ANGELINI FARMACÊUTICA has been chosen by
HELSINN HEALTHCARE as the partner company for the launch in Portugal
of ALOXI® within many other companies eager to in-licence this very
innovative product " said Dr. Luigi Cianci, General Manager of
ANGELINI FARMACÊUTICA. "This acquisition represents a major success
for Angelini, following our strategic decision to enter into the
Oncology Market. We are strongly committed to make of ALOXI® a major
success and to achieve leadership in his Market Segment."
About Chemotherapy-Induced Nausea and Vomiting (CINV)
CINV is estimated to affect 85% of cancer patients undergoing
chemotherapy and can result in a delay or discontinuation of
chemotherapy treatments. The supportive care area is becoming of
paramount importance to help patients deal with adverse events of
anticancer therapies. With good supportive care drugs, cancer
patients are able to tolerate the anti-cancer treatment to a greater
extent, improving their chances of completing their treatment course
successfully with a better quality of life.
About ALOXI®
ALOXI® is a selective 5-HT3-receptor antagonist, developed for the
prevention of CINV, with a long half-life of 40 hours and at least 30
times higher receptor binding affinity than currently available
compounds.  Since its availability in USA in September 2003, there
are over a million and half successful uses of ALOXI®. The product
showed to be effective in preventing both acute and delayed CINV in
patients receiving emetogenic chemotherapies.  For more information
about this product please visit our website: www.palonosetron.net and
www.aloxi.com.
About HELSINN HEALTHCARE
HELSINN HEALTHCARE SA is a privately owned pharmaceutical group
with headquarters in Switzerland and is the worldwide licensor of
ALOXI®.  HELSINN's core business is the licensing of pharmaceuticals
in niche therapeutic areas. The company's business strategy is to
in-license early-stage new chemical entities and complete their
development from the performance of pre-clinical/clinical studies and
CMC development to the attainment of market approvals in strategic
markets (U.S. and Europe).  HELSINN's products are eventually
out-licensed to its marketing partners for distribution.  The active
pharmaceutical ingredients and the finished dosage forms are
manufactured at HELSINN's cGMP facilities and supplied worldwide to
its customers.  For more information about HELSINN, please visit
www.helsinn.com.
About ANGELINI FARMACÊUTICA:
Angelini Farmacêutica is the fully owned Portuguese subsidiary of
ACRAF International, an Italian Multinational Pharmaceutical and
Healthcare Company involved in the Research, Development and
commercialization of a full range of drugs and other healthcare
products. Angelini Farmacêutica is organised with three business
units (Ethical, OTC and Mass Market) and scored a turnover of about ¤
39 million in 2004 achieving the 22nd position in the IMS ranking.

Contact:

HELSINN:
Rachid BenHamza, Ph.D.,
Head Business Unit Oncology & Supportive Care
Phone +41/91/985'21'21
E-Mail: info-hhc@helsinn.com

ANGELINI:
Luigi Cianci, General Manager,
Phone +351/21/414'83'00

Weitere Storys: Helsinn Healthcare SA
Weitere Storys: Helsinn Healthcare SA
  • 13.06.2005 – 12:00

    Exelixis and Helsinn sing agreement for XL119 (Becatecarin)

    South San Francisco, Calif and Lugano, Switzerland (ots) - Exelixis, Inc. (Nasdaq: EXEL) and Helsinn Healthcare S.A. reached an agreement for the development of XL119 (becatecarin). Under the terms of the agreement, Helsinn will pay Exelixis an upfront payment of $4 million and additional milestones up to $21 million. In addition, Helsinn will assume the cost of the Phase III program going forward. In return, Exelixis ...

  • 01.06.2005 – 08:00

    Helsinn Healthcare Licenses a Supportive Care Product from Roche

    Biasca, Switzerland (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and ROCHE today announced the signing of a licensing agreement, granting HELSINN HEALTHCARE the worldwide rights for the patented, phase II product, NETUPITANT. Netupitant is a potent and selective NK-1 receptor antagonist, developed as NKE by Roche, for the prevention of chemotherapy-induced nausea and vomiting (CINV). "We are ...